zenith laboratories inc said company will report fourth quarter loss and amount will determined completion its year end audit company did not elaborate further for third quarter ended sept 1986 zenith reported loss 451 000 dlrs cts per share adjusted for may 1986 for stock split company also said received food and drug administration approval market cefadroxil generic version antibiotic with domestic sales exceeding mln dlrs 1986 zenith said will not market drug until questions relating applicability certain patents have been resolved reuter 